Anti-tnf antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
AssigneeJanssen Biotech, Inc.
InventorsJoseph Hedrick, Elizabeth C. Hsia, Paul Imm, Jocelyn Leu, Bethany Paxson, Mark Rigby, Songmao Zheng, Ramineh Zoka
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods utilizing anti-TNF antibodies having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37 for use in the treatment or prevention of Type I Diabetes (T1D).
Claims16
1-101. (canceled)
At least one isolated mammalian anti-TNF antibody having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37 for use in the treatment or prevention of Type I Diabetes.
A method for treating or preventing a TNF related condition, wherein the TNF related condition is Type 1 Diabetes, the method comprising:
- (a) administering to a subject an isolated mammalian anti-TNF antibody having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37.
A composition comprising at least one isolated mammalian anti-TNF antibody having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37, and at least one pharmaceutically acceptable carrier or diluent for use in the treatment or prevention of Type I Diabetes.
A method for treating or preventing a TNF related condition, wherein the TNF related condition is Type 1 Diabetes, the method comprising:
- (a) administering to a subject a composition comprising an isolated mammalian anti-TNF antibody having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37.
A medical device for use in the treatment or prevention of Type I Diabetes, comprising at least one isolated mammalian anti-TNF antibody having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37, wherein said device is suitable for subcutaneaously (SC) administering said at least one anti-TNF antibody.
Dependencies are inferred from the claim text.